Compare Hims and Hers Health Inc (HIMS) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Microchip Technology Inc. — how do they compare? Hims and Hers Health Inc trades at $29.59 (market cap $7.12B), while Microchip Technology Inc. trades at $79.95 (market cap $43.99B). The key difference: Microchip Technology Inc. is far larger — about 6.2× Hims and Hers Health Inc's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | MCHP | |
|---|---|---|
Market Cap | $7.12B | $43.99B |
Sector | Health | Technology |
52-Week High | $62.76 | $102.97 |
52-Week Low | $14.52 | $49.02 |
Enterprise Value | $7.82B | $49.12B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.
The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.
Microchip Technology (MCHP) trades at $81.39, down 3.9% on the day, amid a bullish technical setup and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.76 exceeding expectations. Recent news highlights robust data center revenue growth (98% last quarter) and strategic acquisitions like Hailo to bolster edge AI capabilities. Valuation metrics remain elevated with a P/E of 119.15, reflecting high growth expectations.
MCHP's outlook is positive with expanding AI infrastructure demand and raised guidance, though high valuation and recent net income pressure in 2025 pose risks. The consensus price target of $104 suggests 28% upside potential. Key risks include execution on growth initiatives and semiconductor cycle volatility. Institutional sentiment remains strongly bullish with no sell ratings among 44 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
